The Revenue Rises
  • Politics
  • Stocks
  • Business
  • Economy
Trending Now
Hedge Market Volatility with These Dividend Aristocrats &...
S&P 500 Bullish Patterns: Are Higher Highs Ahead?
S&P 500 on the Verge of 6,000: What’s...
Clusters of Long Winning Streaks: What They’re Telling...
Three Charts Showing Proper Moving Average Alignment
This California startup is cleaning water and removing...
Shein and Temu see U.S. demand plunge as...
Breakouts, Momentum & Moving Averages: 10 Must-See Stock...
Hedge Market Volatility with These Dividend Aristocrats &...
S&P 500 Bullish Patterns: Are Higher Highs Ahead?

The Revenue Rises

  • Politics
  • Stocks
  • Business
  • Economy
Business

Elon Musk’s Neuralink raises $650 million in fresh capital

by admin June 4, 2025
June 4, 2025
Elon Musk’s Neuralink raises $650 million in fresh capital

Elon Musk’s brain tech startup Neuralink has closed a $650 million funding round, the company announced Monday.

ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, Lightspeed Venture Partners and other firms participated in the round, according to a press release. Neuralink said the fresh capital will help the company bring its technology to more patients and develop new devices that “deepen the connection between biological and artificial intelligence.”

Neuralink is building a brain-computer interface, or BCI, which is a system that translates brain signals into commands for external technologies.

The company’s first system, called Telepathy, involves 64 “threads” that are inserted directly into the brain. The threads are thinner than a human hair and record neural signals through 1,024 electrodes, according to Neuralink’s website.

The initial aim of the technology is to help patients with severe paralysis restore some independence. As of Monday, five patients have been implanted with Neuralink’s technology, and are able to “control digital and physical devices with their thoughts,” the release said.

Neuralink is currently carrying out four separate clinical trials around its Telepathy system.

BCIs have been studied in academia for decades, and several other companies, including Synchron, Paradromics and Precision Neuroscience, are developing their own systems.

Paradromics on Monday announced it successfully implanted its BCI in a human for the first time.

It’s not clear what devices Neuralink will look to develop next, but Musk has for years espoused grand ambitions for the brain tech startup. He has even claimed that he would be willing to get an implant himself.

One of the capabilities Musk has repeatedly highlighted is the ability to restore vision to blind patients.

Neuralink received a “Breakthrough Device” designation from the U.S. Food and Drug Administration for a device called Blindsight. This designation is granted to medical devices that have the potential to provide improved treatment for debilitating or life-threatening conditions.

In a post on his social media platform X in September, Musk said Blindsight will enable even those who have lost both eyes and their optic nerve to see.

Neuralink still has a long road ahead before it can commercialize these technologies.

This post appeared first on NBC NEWS

previous post
Stock Market News UK Update: FTSE 100 & 250 Rise
next post
Oil Prices Rebound After Trump’s Criticism of Powell

Related Posts

United Airlines adds Thailand, Vietnam and Australia flights...

April 3, 2025

Elon Musk’s X and Starlink face nearly $1...

September 21, 2024

Klarna lands buy now, pay later deal with...

March 21, 2025

Target rolls back DEI initiatives, the latest big...

January 26, 2025

Consumer protection board sues Walmart and fintech firm...

December 25, 2024

LVMH and Formula One announce 10-year partnership

October 4, 2024

Amazon AI scammers duped investors out of millions...

March 20, 2025

Abercrombie expects a strong holiday quarter as growth...

November 28, 2024

Rush orders, cut costs, crossed fingers: How small...

December 3, 2024

Millennials reimagine retirement: ‘The end game might not...

February 5, 2025

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Hedge Market Volatility with These Dividend Aristocrats & Sector Leaders
    • S&P 500 Bullish Patterns: Are Higher Highs Ahead?
    • S&P 500 on the Verge of 6,000: What’s at Stake?
    • Clusters of Long Winning Streaks: What They’re Telling Us
    • Three Charts Showing Proper Moving Average Alignment

    Popular Posts

    • 1

      Polls show some good early signs for Kamala Harris

      July 26, 2024
    • 2

      Solana and Cardano: Solana is waiting for a new impulse

      July 18, 2024
    • 3

      The presidential race shifts — modestly, so far — toward Harris

      August 6, 2024
    • 4

      Donald Trump’s imaginary and frightening world

      September 23, 2024
    • 5

      DP Trading Room: PMO Sort on Earnings Darlings

      July 18, 2024

    Categories

    • Business (677)
    • Economy (975)
    • Politics (873)
    • Stocks (770)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: therevenuerises.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 The Revenue Rises. All Rights Reserved.